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Abstract: 
Background: Alzheimer's disease (AD) is a progressive and fatal neurodegenerative 
disorder associated with cognitive decline and is the most common form of dementia 
in the elderly. Early-onset familial AD accounts for less than 1% of AD cases and 
develops before the age of 65 years because of mutations in either the APP gene or 
genes encoding presenilin 1 (PSEN1) or presenilin 2 (PSEN2). The majority of 
sporadic AD cases are referred to as late-onset AD (LOAD) because they occur late in 
life (>65 years). Apolipoprotein E (APOE) polymorphic alleles are the major genetic 
risk factor for AD. The human APOE gene exists as three polymorphic alleles, ε2, ε3, 
and ε4, with a worldwide frequency of 8%, 78%, and 13%, respectively, with ε4 
reaching frequencies of 40% in AD patients. The purpose of this preliminary study 
was to determine ApoE genotype status since no previous association studies between 
LOAD and ApoE gene were available for the Central Algerian population.  
Methods: The cohort of our study was composed of 47 AD patients recruited from the 
Neurology Department of Frantz Fanon Hospital of Blida. Forty-seven controls with 
no type of dementia were also included in the study. All samples were genotyped for 
the ApoE Polymorphisms by PCR-RFLP method. Statistical studies can use the Fisher 
exact test or Chi-2 using the GraphPad Prism 7.0 software. 
Results: The results show that the genotype ɛ3/ɛ3 is most common in both groups 
followed by the heterozygous genotype ɛ3/ɛ4 which showed an increased frequency 
in patients compared to controls (27.66% vs. 12.77%, OR=3.66, IC=0.89-7.9, p=0,11). 
Although rare, all other possible genotypes have been observed in our cohort, namely 
ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4 and ɛ4/ɛ4. The ɛ2/ɛ4 genotype was observed only in AD patients, 
while the ɛ2/ɛ2 genotype was observed only in controls. As expected, the homozygous 
genotype ɛ4/ɛ4 was more frequent in AD patients, compared to controls (6.38% vs. 
2.13%, respectively OR=2.64, IC=0.36-37.33; p=0,33). At the allelic level, ɛ4 allele 
was significantly associated with AD compared to controls (21,28% vs. 4,26% ; OR= 
2.75, 95% CI= 1.109-6.35; p = 0.02, respectively), while the ɛ2 allele seems to be 
protective (4,26% vs. 9,57%, OR = 0.49 ; 95% CI=0.14-1.66 ; p=0,38, respectively), 
but without statistical significance. In population-based studies, the ApoEɛ4-AD 
association was weaker among African Americans (ε4/ε4, OR 5.7) and Hispanics 
(ε4/ε4, OR 2.2) and was stronger in the Japanese population (ε4/ε4, OR 33.1) 
compared with Caucasian cases (ε4/ε4, OR 12.5). The results obtained in our 
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preliminary study indicate that the ApoEɛ4-AD association in the Central Algerian 
population is similar to that observed in the Mediterranean populations. 
Conclusion: We have presented, for the first time in the North Central Algerian 
population, the association of the ɛ4 allele with AD, which could be of great use in the 
diagnosis but also the follow-up of patients with this disease. 
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